Idexx Laboratories Inc (IDXX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Idexx Laboratories Inc  (NASDAQ: IDXX)


Idexx Laboratories Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Idexx Laboratories Inc's ROI in the third quarter of 2026?
Idexx Laboratories Inc achieved a return on average invested assets (ROI) of 53.76 % in its third quarter of 2026, this is above IDXX's average return on investment of 31.57%.
Idexx Laboratories Incs investments during the 12 months ending in the third quarter of 2026 are valued at $2 billion

Despite the deterioration in its net income, company has improved ROI compared to the second quarter of 2026.

Within the Healthcare sector 27 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 89, from total ROI ranking in the second quarter of 2026 at 95.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 2.95 % -3 % -5.61 % -8.95 % -8.56 %
Y / Y Net Income Change TTM 15.06 % 15.62 % 58.35 % 135.97 % 341.26 %
Investment (TTM) in Millions 2,443 2,155 2,086 2,113 2,135
Return On Investment (TTM) 53.76 % 53.7 % 51.9 % 50.26 % 48.1 %
IDXX's Overall Ranking # 89 # 95 # 82 # 108 #
Seq. Investment Change TTM 3.63 % 0.57 % 0.1 % -1.31 % -2.36 %
Seq. Net Income Change TTM 3.73 % 4.06 % 3.38 % 3.12 % 4.24 %
Net Income (TTM) in Millions 1,182 1,140 1,095 1,059 1,027

IDXX Company Profile >> Back to IDXX Roi Comparisons >> See Annual IDXX Return On Investment



Return On Investment IDXX's Ranking
Within: No.
Industry # 0
Sector # 28
Overall # 89

Return On Investment Statistics
High Average Low
51.8 %
31.57 %
16.37 %
(Jun 30 2026)   (Sep 30 2015)







Financial Statements
Idexx Laboratories Inc's III. Quarter Investments $ 2,443 Millions IDXX's Balance sheet
Idexx Laboratories Inc's III. Quarter Income $ 317 Millions Quarterly IDXX's Income Statement
IDXX's Income by Division See IDXX's Income by Division


IDXX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,202 2,226 2,308 1,511 1,674
Y / Y Investment Growth -1.06 % -3.59 % 52.78 % -9.72 % -2.27 %
Net Income in Millions 1,059 888 845 679 745
Y / Y Net Income Growth 19.33 % 5.07 % 24.44 % -8.83 % 27.95 %
Annual Return On Investment 48.11 % 39.89 % 36.61 % 44.94 % 44.5 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 48.11 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IDXX's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IDXX's Competitors
Subscribers only: Roi for Idexx Laboratories Inc's Suppliers
Subscribers only: Return On Investment for IDXX's Customers

Other Ratios
IDXX's Roa IDXX's Inventory Turnover Ratio IDXX's Growth Rates IDXX's Dividend Statistics
IDXX's Profitability Ratios IDXX's Asset Turnover Ratio IDXX's Dividend Growth
IDXX's Roe IDXX's Valuation Ratios IDXX's Financial Strength Ratios IDXX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Arbutus Biopharma Corp  120.80 %
Indivior Pharmaceuticals Inc   108.22 %
Lensar Inc   94.32 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %

Date modified: 2026-11-03T10:00:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.